We produced nine monoclonal antibodies (MAbs) directed against the West Nile virus E glycoprotein using three different immunization strategies: inactivated virus, naked DNA, and recombinant protein. Most of the MAbs bound to conformation dependent epitopes in domain III of the E protein. Four of the MAbs neutralized WNV infection and bound to the same region of domain III with high affinity. The neutralizing MAbs were obtained from mice immunized with inactivated virus alone or in combination with a DNA plasmid. In contrast, MAbs obtained by immunization with a soluble version of the E glycoprotein did not exhibit neutralizing activity. These non-neutralizing antibodies were cross-reactive with several other flaviviruses, including Saint Louis encephalitis, Japanese encephalitis, Yellow Fever and Powassan viruses. Interestingly, some non-neutralizing MAbs bound with high affinity to domains I or III, indicating that both affinity and the precise epitope recognized by an antibody are important determinants of WNV neutralization. D
Introduction
West Nile virus (WNV), the etiologic agent of West Nile virus fever and encephalitis, is an emerging human and veterinary pathogen in the Western Hemisphere. WNV was first isolated in the United States in 1999, and has since spread rapidly throughout North America and the Caribbean. WNV is a member of the genus Flavivirus, family Flaviviridae, and is related to other arthropodborne viruses including dengue virus, Japanese encephalitis virus, Saint Louis encephalitis virus and tick-borne encephalitis virus. Phylogenetic analysis demonstrates that two related groups of WNV exist in nature (lineage I and II), though only lineage I viruses have been associated with disease outbreaks worldwide, including the current epidemic in the United States (Berthet et al., 1997; Lanciotti et al., 1999) .
WNV virions contain two surface glycoproteins, premembrane/membrane (prM/M) and envelope (E). The membrane protein (M) is synthesized as a precursor (prM) that acts as a chaperone during the folding and maturation of the E protein (Konishi and Mason, 1993; Lorenz et al., 2002) . Flavivirus prM and E proteins form a heterodimer (Allison et al., 1995a; Wengler and Wengler, 1989) with prM probably protecting the E protein from acid inactivation during transport in intracellular vesicles (Heinz and Allison, 2000) . After cleavage of prM into M by furin during intracellular transport (Stadler et al., 1997) , dissociation of the prM/E heterodimer occurs and E homodimers are formed (Kuhn et al., 2002; Zhang et al., 2003) . E dimers, arranged in a bherringboneQ pattern, form a protein shell on the surface of mature flavivirus virions (Kuhn et al., 2002; Mukhopadhyay et al., 2003) . The E protein is responsible for mediating virus entry and is the major target for neutralizing antibodies. Structural studies of tick-borne encephalitis virus and dengue virus reveal that the E protein of flaviviruses folds into three structural domains: I, II and III (Modis et al., 2003; Rey et al., 1995) . Domain I, the central domain, contains a single N-linked glycosylation site and forms part of a hinge region that undergoes conformational changes upon exposure of the protein to low pH, in conjunction with Domain II (Bressanelli et al., 2004; Modis et al., 2004) . Domain II, the dimerization domain, contains a highly conserved hydrophobic loop which inserts into the host cell membrane during fusion (Allison et al., 2001; Bressanelli et al., 2004; Modis et al., 2004) . Domain III is the putative receptor binding domain (Bhardwaj et al., 2001; Crill and Roehrig, 2001; Hung et al., 2004) and an important target for neutralizing antibodies. Antibodies that bind to the E protein could prevent infection of cells by blocking attachment of virus to cellular receptors and attachment factors (Crill and Roehrig, 2001; He et al., 1995) , or by blocking fusion with the cell membrane after viral attachment (Butrapet et al., 1998; Gollins and Porterfield, 1986; Guirakhoo et al., 1991; Roehrig et al., 1998; Stiasny et al., 2002) .
Several lines of evidence suggest an important role for antibodies in protection from and clearance of WNV. Passive immunization with antibodies against WNV can prevent disease in animals infected with WNV (Ben-Nathan et al., 2003; Camenga et al., 1974; Diamond et al., 2003; Engle and Diamond, 2003; Tesh et al., 2002; Wang et al., 2001 ). In addition, B-cell-deficient mice are more susceptible to WNV than mice with an intact humoral immune system Halevy et al., 1994) . Clinical case reports of human WNV patients who exhibited neurologic symptoms but recovered after treatment with human immunoglobulin preparations containing WNV antibodies suggest that administration of WNV-specific antibodies could be of therapeutic value (Agrawal and Petersen, 2003; Haley et al., 2003; Hamdan et al., 2002; Shimoni et al., 2001 ).
Relatively few monoclonal antibodies (MAbs) against WNV have been described and fully characterized (Adams et al., 1995; Beasley and Barrett, 2002; Besselaar and Blackburn, 1988; Hall et al., 1991; Mathiot et al., 1990; Peiris et al., 1982) . Using three different immunization strategies, we produced and characterized nine MAbs against WNV. Most of the MAbs bound to conformation-dependent epitopes in domain III and reacted with a lineage I and lineage II virus strain. MAbs produced by immunization with a soluble form of the E protein cross-reacted with several other flaviviruses, but did not exhibit virus-neutralizing activity. MAbs produced by immunization with a formalin-inactivated virus vaccine, or a combination of formalin-inactivated vaccine and a DNA vaccine, were WNV-specific and a subset neutralized virus infection. For antibodies that blocked WNV infection, neutralization potency correlated with binding affinity. However, some non-neutralizing MAbs bound with high affinity to epitopes that partially overlapped with those recognized by neutralizing MAbs. Thus, relatively subtle differences in MAb binding to the E protein can significantly impact virus neutralization.
Results

Production of MAbs to the Envelope proteins of WNV
Immunization with different forms of flavivirus envelope proteins has the potential to produce antibodies with different properties (Aberle et al., 1999; Heinz et al., 1995; Raviprakash et al., 2000) . To increase the possibility of obtaining MAbs to a variety of epitopes, we employed three different methods to produce and deliver WNV immunogens (see Table 1 ). In the first immunization protocol, mice were immunized with a formalin-inactivated virus vaccine licensed for horses (West Nile Innovator-Fort Dodge Animal Health) (Ng et al., 2003) . In the second protocol, mice were vaccinated with a DNA plasmid encoding lineage I WNV surface glycoproteins prM and E (pCBWN) (Davis et al., 2001) , followed by booster injections with the formalin-inactivated virus vaccine. The third immunization protocol utilized a soluble form of the WNV E protein produced by expressing a truncated form of E protein lacking the two transmembrane anchors as a polyprotein with prM, a configuration shown previously to allow interaction of E with prM and secretion from cells (Allison et al., 1995a) .
Hybridomas were screened by ELISA using two different antigens, subviral particles (SVPs) or soluble E protein, depending on the immunogen utilized. For mice immunized with DNA and the formalin-inactivated virus vaccine, subviral particles (SVPs) were used as the antigen. SVPs are secreted from cells expressing full-length prM and E proteins, and closely resemble native virus particles antigenically and functionally (Allison et al., 1995a; Chang et al., 2000; Davis et al., 2001; Hunt et al., 2001; Konishi and Fujii, 2002; Konishi et al., 1992 Konishi et al., , 2001 Kroeger and McMinn, 2002; Mason et al., 1991; Schalich et al., 1996) . Since SVPs are not infectious, they can substitute for virus in a variety of assays and were chosen as the antigen for these ELISAs. For mice immunized with the soluble E protein, the same soluble protein was used as the antigen in the screening ELISA. Three MAbs were obtained from each immunization approach: formalin-inactivated virus (17C8, 8B10, 10C5), DNA followed by formalin-inactivated virus (17D7, 11C2, 6G10) and soluble E (4E1, 3F7, 9E5) (Table 1) . These MAbs were isotyped, purified from hybridoma supernatants and immunoglobulin concentrations determined by ELISA.
Characterization of MAbs
To determine which viral surface glycoprotein the MAbs recognized and to discriminate between MAbs recognizing linear and discontinuous epitopes, we examined the ability of the MAbs to detect prM or E by immunoblotting. 293T cells were transfected with pCBWN, and cell lysates analyzed under two different conditions in SDS-PAGE: complete and partial denaturation. All MAbs recognized the E protein by immunoblot under partially denaturing conditions (NR), while three of the MAbs (17D7, 4E1, 3F7) also recognized the E protein under fully denaturing conditions (R) ( Table 1 , data not shown). This suggests that six of the MAbs are directed against discontinuous epitopes in the E protein, while three of the MAbs (17D7, 4E1 and 3F7) recognized epitopes that persist after denaturation and reduction.
We next determined if the MAbs could detect WNV E protein expressed in cells transfected with pCBWN by immunofluorescence and immunoprecipitation techniques (Table 1) . Using immunofluorescence, all MAbs detected an intracellular reticular pattern consistent with localization of the E protein in the endoplasmic reticulum, as previously described (Mackenzie and Westaway, 2001 , Hanna et al., manuscript in preparation) (data not shown). Seven out of nine MAbs immunoprecipitated the E protein from cell lysates, although two of these MAbs (17D7 and 9E5) were less efficient than the others (data not shown). These seven MAbs also co-immunoprecipitated the prM protein from cell lysates, confirming that prM and E form stable complexes within the cell (Lorenz et al., 2002) . Two MAbs did not immunoprecipitate E under these conditions, 3F7 and 6G10, suggesting that these MAbs may recognize epitopes that are either lost upon detergent extraction, buried when E exists in a complex with prM or another E monomer, or may have a lower affinity towards the detergent solubilized E protein.
Epitope mapping
Based on the crystal structures of the E protein from dengue virus and tick-borne encephalitis virus, the E protein of WNV folds into three structural domains (Fig. 1A) (Modis et al., 2003; Rey et al., 1995) . Three different techniques were used to further define the epitopes recognized by the panel of MAbs on the WNV E protein: production of E protein fragments as bacterial fusion proteins, competition binding ELISA studies, and site-directed mutagenesis of the E protein. Small fragments of the E protein ectodomain were produced in bacteria as thioredoxin fusion proteins, termed WE1 through 7 (Fig. 1B) . Lysates of bacteria expressing the different fragments were run on SDS-PAGE under partially denaturing conditions, and antibody recognition of the fragments assessed by immunoblotting. Six of the nine MAbs recognized fragment WED3, which consisted of residues 296-415 of domain III from lineage I WNV strain NY99-6480 (Fig. 1C) . For West Nile and other flaviviruses, production of domain III by itself in bacteria results in a molecule whose conformation is similar to that of domain III in the native E protein (Bhardwaj et al., 2001; Volk et al., 2004; Wu et al., 2003; Yu et al., 2004) . However, these MAbs failed to map to smaller fragments of domain III (WED3-1, WED3-2, WED3-3), suggesting that they recognized conformational epitopes conserved in the bacterial protein encoding the majority of domain III, but lost when domain III was disrupted. One MAb, 17D7, mapped to two fragments, WE2 (residues 146-249) and WE4 (residues , indicating that its epitope mapped to domain I. Two MAbs, 6G10 and 9E5, did not recognize any of the E protein fragments by immunoblotting. When reactivity was assessed by ELISA with a subset of non-denatured protein fragments, 9E5 reacted with WED3 (Domain III), suggesting that its epitope was conformationally sensitive, while 6G10 remained nonreactive.
To determine if the MAbs bound to overlapping epitopes on the surface of the E protein, we tested the MAbs using a competition binding ELISA. For these studies, SVPs were used as the antigen bound to the ELISA plates. Saturating concentrations of unlabeled MAbs were incubated with the SVPs, after which a biotinylated bcompetitorQ MAb was added. If preincubation of SVPs with an unlabeled MAb blocked subsequent binding of a biotinylated MAb, it can be concluded that the MAbs bind to similar or at least overlapping epitopes. The MAbs were categorized into six groups based on the results of this competition-binding assay (Fig. 2D ). MAbs 17D7 and 6G10 did not compete significantly with any of the other MAbs tested, although 17D7, which mapped to domain I, partially blocked binding of several domain III MAbs (Figs. 2A and B) . MAbs which mapped to domain III were categorized into four different groups. The first group consisted of MAbs 8B10, 11C2, 10C5 and 17C8. When 8B10 or 11C2 were used as the unlabeled antibody, biotinylated 17C8 or 10C5 were not able to subsequently bind to the antigen ( Fig. 2A and data not shown). However, when MAbs 10C5 or 17C8 were used as the unlabeled antibody, 8B10 and 11C2 were able to subsequently bind antigen ( Fig. 2B and data not shown). This non-reciprocal competition is most likely due to the fact that 17C8 and 10C5 bound to E protein with a lower affinity than MAbs 8B10 and 11C2 (see Table 1 ). Thus, we conclude that these four MAbs bind to essentially the same epitope on domain III. The other three domain III MAbs, 4E1, 9E5 and 3F7, did not significantly compete with any of the other MAbs tested in this assay, although some partially blocked binding of other domain III MAbs (data not shown). Partial competition could be due to differences in affinity, to antibody-induced conformational changes in E protein upon antibody binding or steric hindrance. For example, binding of a domain I MAb to one E monomer could partially prevent binding of a domain III MAb to an adjacent E monomer, as was seen with MAb 17D7.
Site-directed mutagenesis of the E protein was used to investigate the specific amino acid residues important for binding of domain III antibodies. Mutations of specific amino acid residues were made based on analysis of the structure of the WNV and Dengue E proteins (Modis et al., 2003; Volk et al., 2004) , and MAb mapping results with neutralization escape mutants from other flaviviruses and WNV (Beasley and Barrett, 2002; Roehrig, 2003) . All studied amino acid residues were mutated to alanines, except for two mutations (positions 307 and 330) previously described as important targets for WNV neutralizing antibodies (Beasley and Barrett, 2002) . SVPs were produced by transfection of 293T cells, and attached to the ELISA wells. Binding of each MAb to the mutant SVPs was normalized to binding of the MAb to the wild-type SVP, and shown as percentage of wild-type binding (Table 3) . Results from sitedirected mutagenesis confirmed that MAbs 8B10, 10C5, 17C8 and 11C2, which bind to domain III and compete in the competition binding assay, map to the same cluster of amino acid residues on the lateral surface of domain III (including residues 306, 307, 330 and 332) (Table 3) , though the contacts made with this small region of domain III varied slightly between the antibodies. All four MAbs were affected by mutations in residues 307 and 330, while only MAb 17C8 was affected by the mutation in 306, and MAb 11C2 affected by the mutation in 332 (Table 3 ). This area of Domain III has been described previously as a target of potent neutralizing MAbs for a variety of flaviviruses, including WNV (Beasley and Barrett, 2002; Chambers et al., 1998) . Additional mutagenesis of neighboring residues on the lateral surface of domain III did not significantly affect binding of specific MAbs (Table 3) . Interestingly, mutations that prevented binding of neutralizing MAbs did not abrogate infectivity (data not shown), suggesting that these residues are not critical for function of the E protein, as previously suggested (Beasley and Barrett, 2002) .
Since the E protein of flaviviruses undergoes irreversible conformational changes at low pH (Allison et al., 1995b; Bressanelli et al., 2004; Heinz and Allison, 2000; Modis et al., 2004) , we studied if any of the epitopes recognized by these MAbs were affected by treatment of virus with low pH. While domain III epitopes are usually not affected by low pH treatment, domain I and II epitopes can be altered or lost due to the large rearrangements that occur in these domains at low pH (Bressanelli et al., 2004; Modis et al., 2004; Roehrig, 2003) . West Nile virions were treated at low pH (pH 4) or neutral pH (pH 8), back-neutralized to pH 8 and used as the antigen in an ELISA. Plaque assays showed that low pH treated virus was inactivated while virus treated at neutral pH remained infectious, confirming that low pH treatment triggered irreversible conformational changes in the E protein that inhibited virus entry and infection (data not shown). However, all MAbs recognized viruses treated at low or neutral pH, indicating that the epitopes recognized by these MAbs were not lost during the pH-induced conformational changes although small differences in the reactivity of the antibodies were sometimes observed (data not shown).
Cross-reactivity of MAbs with Lineage II WNV and other flaviviruses
We examined if the MAbs would recognize a prototypic lineage II E protein (WNV 956 D117 3B) (Yamshchikov et al., 2001 ) in addition to the lineage I E protein described above. The E proteins of these two strains differ in 25 out of 502 amino acid residues, with the Lin II strain lacking a glycosylation site (Yamshchikov et al., 2001) . For these experiments, we used a lineage II envelope protein which had the glycosylation site inserted by mutagenesis, as we have found that this results in higher levels of SVP production (Hanna et al., manuscript in preparation). Lineage I and II SVPs were obtained by transfecting cells with plasmids encoding the prM and E proteins from each strain. The SVPs were captured to the wells of an ELISA plate and incubated with each of the MAbs. All MAbs detected both lineage I and II SVPs, although some MAbs had decreased reactivity to lineage II relative to lineage I (17D7, 6G10, 3F7), suggesting subtle antigenic differences may exist between these two strains (data not shown).
Given the close phylogenetic and antigenic relationships between flaviviruses, we tested each MAb for the ability to cross-react with a panel of related flaviviruses. Vero cells were infected with the indicated virus (Table 2), after which immunofluorescence was performed. We found that three of the MAbs (4E1, 3F7 and 9E5) were cross-reactive with other flaviviruses. These three MAbs recognized not only members of the Japanese encephalitis serocomplex (Saint Louis encephalitis and Japanese encephalitis virus), but also more distantly related flaviviruses (Yellow Fever and Powassan virus) ( Table 2 ). None of the MAbs reacted with Dengue virus 2, nor with the other viruses tested (Western Equine Encephalitis virus, Venezuelan Equine Encephalitis virus, Eastern Equine Encephalitis virus, LaCrosse virus). Only the three MAbs made by immunization with the soluble E protein showed cross-reactivity in this assay, while the remaining six MAbs made by immunization with DNA or formalininactivated virus were specific for WNV epitopes.
Neutralization profiles of MAbs
The neutralization profile of the MAbs was assessed using a plaque reduction neutralization assay. Four MAbs (11C2, 17C8, 10C5 and 8B10), all of which bound to the same or highly similar epitopes in domain III, showed neutralizing activity using this approach, albeit with different potency (Table 1) . MAbs 8B10, 11C2 and 10C5 showed the strongest neutralizing activity, while MAb 17C8 only neutralized WNV when very high concentrations of antibody were present (N250 Ag/ml). Among the four neutralizing MAbs, those that bound with the highest affinity exhibited the most potent neutralization activity (Table 1) . However, high affinity binding alone did not predict neutralizing activity since some MAbs that failed to neutralize WNV also bound with high affinity (i.e., 4E1, 17D7) (Table 1) . Therefore, both affinity and the specific epitope recognized by the antibody are important determinants for neutralization of WNV.
Discussion
West Nile virus, an emerging infectious pathogen in the Western Hemisphere, is responsible for viral encephalitis epidemics worldwide. The importance of an intact antibody response for reducing morbidity and mortality of WNV infected animals has been established through studies in animal models Halevy et al., 1994) , though the nature and character of the humoral immune response in humans and other important animal hosts for WNV is not well understood. In humans, several case reports suggest that neutralizing antibodies may have a role in recovery from WNV infection (Agrawal and Petersen, 2003; Haley et al., 2003; Hamdan et al., 2002; Shimoni et al., 2001) . In order to develop systems to understand the neutralization of WNV by antibodies both in vivo and in vitro, we produced a panel of MAbs to the E glycoprotein of WNV and mapped their epitopes by several techniques.
To increase the probability of obtaining a diverse repertoire of MAbs, we utilized four different strategies to elicit WNV specific MAbs. First, we utilized a formalin- Table 2 Analysis of cross-reactivity of MAbs against other flaviviruses by immunofluorescence WNV = West Nile Virus, SLE = Saint Louis Encephalitis Virus, JEV = Japanese Encephalitis Virus, YFV = Yellow Fever Virus, POW = Powassan Virus. The numbers on the table refer to fluorescence intensity with 4 = to highest intensity and 0 = no staining. Only MAbs which showed crossreactivity are shown (shaded boxes). Table 3 Epitope mapping by site-directed mutagenesis Results of MAb binding to wild-type (WT) or mutated E proteins in the context of subviral particles (SVP). The binding of each MAb to WT SVPs was set to 100%, and binding of each MAb to the mutated E proteins was expressed as a pecentage of WT binding. Shaded in gray are results from mutations which significantly affected binding of specific MAbs. Location of these mutations is depicted in Fig. 1A . Data in each table represent mean values from two independent experiments done in duplicate.
inactivated WNV vaccine, which has a high degree of efficacy in horses, although the humoral response that it elicits has not been extensively characterized (Ng et al., 2003) . While formalin-inactivation may alter the antigenic conformation of the surface glycoproteins, increasing the possibility of obtaining antibodies against epitopes that may differ from those in the native virus , formalin-inactivated human vaccines have been successfully used for other flaviviruses (Barrett, 2001; Nalca et al., 2003) . Second, we immunized mice with a nucleic acid construct encoding the prM and E proteins of WNV (pCBWN). Immunization with this DNA was expected to result in the production of subviral particles that closely reflect native WNV structure. Previous studies demonstrate that vaccination with pCBWN elicits a protective immune response in mice and horses (Davis et al., 2001 ). Third, we immunized mice with the DNA vaccine followed by boosters with the formalin-inactivated vaccine. The neutralizing antibody response in the serum of mice immunized with DNA was stronger after boosting with the formalininactivated virus vaccine (data not shown); therefore, we chose these animals for hybridoma production. Finally, we produced a soluble WNV E protein for use as an immunogen. Soluble proteins have been used to obtain the crystal structures of Tick-borne encephalitis and Dengue E proteins (Bressanelli et al., 2004; Modis et al., 2003 Modis et al., , 2004 Rey et al., 1995) , which have revolutionized our understanding of the conformation and function of these proteins. Soluble E proteins may present epitopes that are masked when using antigens in particulate form (i.e., virus and subviral particles) but should preserve the overall conformation of the protein. However, none of the MAbs produced to the soluble E protein were neutralizing. This could be due to structural differences between soluble and virion associated E proteins, the presence of immunodominant epitopes in the soluble protein that are masked when the E protein is on the surface of a particle, differences in hybridoma screening, or the limited number of antibodies that we obtained. Interestingly, these 3 MAbs exhibited significant cross-reactivity with other flaviviruses, whereas the MAbs elicited by other immunogens reacted only with WNV.
While neutralizing epitopes have been described in all three domains of the E protein for other flaviviruses (for review, see Roehrig, 2003) , the majority of neutralizing antibodies bind to domain III. The four neutralizing MAbs described here (8B10, 11C2, 10C5 and 17C8) mapped to a region on the lateral surface of domain III which has been previously described as an important neutralizing epitope for WNV (Beasley and Barrett, 2002; Chambers et al., 1998 ) (see Fig. 1A and Table 3 ). Despite this, they neutralized virus infection with different potencies, with their ability to block virus infection directly correlating with their affinity to the E protein (Table 1 ). It will be interesting to determine if very high affinity binding of MAbs to WNV is due to bivalent binding, since the complex structure of the protein shell covering the virus makes bivalent binding on different E proteins feasible (Mukhopadhyay et al., 2003) . In addition, subtle differences in the amino acid residues bound by each MAb could also impact neutralization. We expect that additional mutations will further differentiate the specific epitopes for these neutralizing MAbs.
Non-neutralizing MAbs mapped to domains I or III and had a variable affinity for the E protein (see Table 1 ). Several MAbs that bound to the E protein with high affinity exhibited no neutralizing activity (4E1, 9E5, 17D7). It is possible that high affinity MAbs which do not neutralize WNV in vitro may be protective in vivo by mechanisms other than blocking interaction of the virus with the cell, including complement or Fc-dependent mechanisms. Therefore, for WNV, binding to the E protein with high affinity is not sufficient for neutralization suggesting that both affinity and the specific nature of the epitope are key components for effective neutralization of WNV.
High occupancy theories of antibody neutralization predict that complete coating of the virus by antibodies is sufficient to neutralize virus, by blocking interactions with the cell (Klasse and Sattentau, 2002) . Our neutralization and affinity data suggest that coating of West Nile virions with high affinity antibodies is not the only determinant of neutralization. It is not clear if non-neutralizing, high affinity antibodies against flaviviruses allow functional epitopes on the E protein to be exposed even when the particle is covered with antibodies, thereby allowing virus entry. It is also possible that steric hindrance prevents complete coverage of the virus particle by these MAbs, allowing some E proteins to interact with the cell and mediate entry (Klasse and Sattentau, 2002) .
Passive immunization with antibodies against WNV can confer protection in animal models (Ben-Nathan et al., 2003; Camenga et al., 1974; Diamond et al., 2003; Engle and Diamond, 2003; Tesh et al., 2002; Wang et al., 2001 ). Passive immunization with pooled human plasma preparations (intravenous immunoglobulin, IVIG) containing neutralizing antibodies against WNV (Omr-IgG-am, Omrix Pharmaceuticals) is currently undergoing clinical trials in the United States (http://www2.niaid.nih.gov/newsroom/ releases/wnv _ trials.htm) reflecting the success of this approach in a limited number of clinical case reports (Agrawal and Petersen, 2003; Haley et al., 2003; Hamdan et al., 2002; Shimoni et al., 2001) . Treatment with humanized MAbs is a viable, more specific alternative treatment for WNV infection than treatment with IVIG. Treatment with humanized MAbs can eliminate the risk of accidental transmission of infectious diseases which may be present in the IVIG preparations. Potentially, humanized MAbs may be used as an adjunct therapy to IVIG in order to increase the titer of neutralizing and protective antibodies in the preparations used for treatment. Safety and effectiveness of humanized, neutralizing, high affinity MAbs should therefore be investigated as a therapy for WNV.
Materials and methods
WNV immunogens
Mice were immunized with three different forms of the WNV E protein: a DNA plasmid encoding the prM and E genes of Lineage I WNV strain NY99-6480 (pCBWN) (Davis et al., 2001 ), a formalin-inactivated virus vaccine licensed for use in horses (West Nile Innovator-Fort Dodge Animal Health) (Ng et al., 2003) , and purified soluble WNV E protein. For the WNV soluble E protein, a PCR product encoding the prM gene and a truncated E gene (truncated at amino acid 440 of the NY99-6480 strain) with a 6X-Histidine tag at the 3V end, was cloned into pSC65 using the restriction enzymes SalI and BglII. A recombinant vaccinia virus, vBAP29, was produced using this plasmid and the Western Reserve vaccinia virus strain, using standard techniques (Earl and Moss, 1993) . To generate recombinant protein, HEK 293T cells were infected with vBAP29 at a multiplicity of infection of 5 for 1 h, then washed twice with phosphate-buffered saline (PBS) and media replaced with serum-free Dulbecco-modified Eagle medium (DMEM; Gibco-BRL). Cell supernatants were harvested 48 h postinfection, clarified by low-speed centrifugation, and filtered through a 0.22-Am-pore size filter. Triton X-100 was added to a final concentration of 0.1% to inactivate residual vaccinia virus and sodium azide was added to 0.05% to prevent microbial growth. Media were concentrated and dialyzed against PBS with a Millipore tangential flow filtration system and 30K Biomax Pellicon membrane. Soluble E was purified from the diafiltrate on Talon resin (Clontech) using a Biologic LP chromatography system (BioRad). Resin was equilibrated with PBS, supernatant applied, then washed with PBS, followed by a PBS 20 mM imidazole wash, and protein eluted with 200 mM imidazole in PBS. Eluate was concentrated and buffer exchanged with PBS in a Centriplus 30 centrifugal concentrator (10 kDa MW cutoff) and protein concentration determined by BCA Protein Assay (Pierce) with a BSA standard curve. Purity of the soluble E protein was assessed by silver stain analysis.
Monoclonal antibody production
Groups of 6-to 8-week-old BALB/c mice were divided into three groups for immunization with one of three different protocols. For immunization protocols using the formalin-inactivated virus vaccine, mice were immunized four times with 100 Al of the vaccine intramuscularly (IM) at 3-week intervals, followed by two intraperitoneal (IP) boosts with 100 Al of the vaccine at 3-week intervals, and a final intravenous (IV) injection with 25 Al of the vaccine 4 days before hybridoma fusion protocols were performed. Splenocytes from one mouse were harvested and fused with SP2 myeloma cells as described previously (Yokoyama, 1994) . Hybridomas were screened by enzyme-linked immunosorbent assay (ELISA) for reactivity against WNV subviral particles (SVP). Positive hybridoma cells were cloned by limiting dilution to obtain antibodies derived from a single cell.
For immunization protocols using the DNA plasmid (pCBWN) and the formalin-inactivated virus vaccine, 100 Ag of DNA (pCBWN) was injected IM for three doses at 3-week intervals, with three IM boosts with 100 Al of the formalin-inactivated virus vaccine, one IP boost with 100 Al of the formalin-inactivated virus vaccine and a final IV boost with 25 Al of the killed virus vaccine 4 days before the fusions were performed as described above. These hybridomas were also screened for reactivity against WNV SVPs using an ELISA and cloned by limiting dilution.
For immunization protocols using the soluble E protein, 100 Ag of purified protein in Ribi Adjuvant System (MPL + TDM Emulsion, Corixa Corporation) was injected intradermally (ID) for five doses at 3-week intervals, with a final IV boost with 100 Ag of purified protein without adjuvant. Four days after the final immunization, fusions were performed following the same protocols for the previous two fusions. These hybridomas were screened for reactivity against purified WNV soluble E protein using an ELISA, and cloned by limiting dilution. A total of five fusions were performed, out of which nine stable hybridoma cell lines were isolated and further characterized. MAbs were isotyped by using an ELISA-based isotyping kit (Clonotyping System-HRP, Southern Biotechnology Associates).
Production of wild-type and mutant subviral particles
SVPs were produced by lipid-mediated transfection of HEK 293 T cells with a DNA plasmid encoding wild-type Lin I or Lin II prM/E, or mutants of these proteins, following manufacturer's instructions (Lipofectamine 2000, Invitrogen) . For Lineage I WNV, strain NY99-6480 (pCBWN) was used, while for Lineage II WNV, strain 956 D117 3B (Yamshchikov et al., 2001 ) was used. Five to 6 h after transfection, the media were changed to low-glucose formulation of DMEM supplemented with 1% Penicillin/ Streptomycin (no serum). Supernatants containing SVPs were harvested 48 h after transfection, clarified by lowspeed centrifugation, filtered through a 0.45 Am-pore size filter, and stored at 4 8C. For the lineage I vs. lineage II ELISA described below, SVPs were produced in lowglucose DMEM supplemented with FBS, and pelleted by ultracentrifugation through a 20% sucrose cushion at 38,000 rpm for 2 h at 4 8C in a Beckman SW41Ti rotor. The SVP pellet was resuspended overnight in 150 mM NaCl, 10 mM HEPES, pH 8.0.
SVPs with mutations in Domain III of the lineage I WNV E protein were produced in low-glucose serum-free DMEM as described above by transient transfection of HEK 293T cells with a plasmid encoding wild-type prM and a mutated E protein. The following amino acid residues in Domain III were mutated on the pCBWN plasmid using the QuikChange Site-Directed Mutagenesis kit (Stratagene): S306A, K307R, F309A, K310A, L312A, H320A, Q328A, Y329A,  T330I, T332A, T366A, N368A, K370A, I384A, V385A , V386A, G389A, Q391A. Sequence analysis of the entire open-reading frame confirmed that the only mutations present were those listed above. Mutations of specific amino acid residues were made based on analysis of the structure of a homology model of the WNV E protein based on the crystal structure of the Dengue E protein (PDB code, 1OAN) (Modis et al., 2003) obtained with the program 3D-Jigsaw (http://www.bmm.icnet.uk/servers/3djigsaw/) and visualized with Rasmol 2.6 (Sayle and Milner-White, 1995) , the NMR structure of WNV Domain III (PDB code, 1S6N) (Volk et al., 2004) , and MAb mapping results with neutralization escape mutants from other flaviviruses and WNV (Beasley and Barrett, 2002; Roehrig, 2003) . Dilution experiments of mutant SVPs suggested that similar levels of protein were produced by all the mutant envelope proteins (data not shown).
ELISAs
All ELISAs were performed in 96-well plates (Immulon 2 HB, Thermo Labsystems). SVP refers to those produced by transfection with pCBWN unless otherwise noted. For hybridoma screening, a 32-fold dilution of serum-free supernatant containing SVPs was added to each well in PBS pH 8.6 and allowed to bind overnight at 4 8C. We found that this dilution of the SVP preparations in serumfree supernatant consistently saturated binding of SVPs to the wells of the ELISA plate (data not shown). After overnight binding of SVPs, the plates were washed six times using an automatic plate washer (Ultrawash PLUS Microplate Washer, Dynex Technologies) with PBS/0.05% Tween 20, and blocked with BLOTTO (PBS with 5% nonfat dry milk and 0.1% Tween 20) for 1 h at room temperature (RT). Hybridoma supernatants (100 Al) were added after the blocking step and allowed to bind for 2 h at RT. Plates were washed six times, and ECL anti-mouse IgG from sheep conjugated to horseradish peroxidase (HRP) (Amersham Biosciences) was added at a dilution of 1:10,000 and incubated for 1 h at RT. Following a final wash, TMB Peroxidase Substrate and Peroxidase Substrate solution B (KPL) were mixed at 1:1 dilution, 100 Al added to each well, the reaction stopped with 50 Al 2MH 2 SO 4 per well, and optical density at 450 nm (OD 450 ) measured. ELISAs to screen for positive hybridomas using soluble E-His protein were performed similarly to the SVP ELISAs, using instead 100 ng of purified soluble E protein per well as the antigen.
ELISAs to test binding of MAbs to SVPs with mutations in Domain III were performed as described above for the SVP ELISAs for hybridoma screening with the following adjustments: a 4-fold dilution of the specific mutant SVPs was added as the antigen in the ELISA plates, and incubated with 30 Ag/ml of each MAb as the primary antibody. A 4-fold dilution of mutant SVPs consistently saturated binding to the wells of the ELISA plate. Some of the mutated constructs did not express enough protein and therefore were excluded from this assay. The binding of each MAb to the mutant SVPs was normalized to the reactivity of each MAb with wild-type SVPs, with binding to wild-type SVPs set to 100%.
ELISAs to test lineage I versus lineage II SVPs were performed as described for the SVP ELISA for hybridoma screening with the following adjustments: SVPs used were made in the presence of FBS and pelleted through a 20% sucrose cushion as described above, a 10-fold dilution of lineage I and lineage II SVPs was coated on the wells, and 0.1 mg/ml of each MAb was used as the primary antibody. Dilution experiments with both SVPs suggested they were produced at similar levels (data not shown).
Competition binding ELISAs were performed in 96-well plates to which SVPs in serum-free media had been adsorbed in ELISA coating buffer (0.15 M sodium carbonate, 0.35 M sodium bicarbonate in PBS pH 9.6) overnight at 4 8C. Plates were washed with PBS/0.05%Tween 20 and blocked with PBS/0.05% Tween/1% BSA for 1 h at RT. Unlabeled MAbs were diluted at 200 Ag/ml in PBS/ 0.05% Tween/1% BSA and incubated at RT for 1 h. After incubation with the unlabeled MAb, the indicated biotinylated bcompetitorQ MAb was added at 2 Ag/ml without washing and the plate was incubated for 30 min at RT. Plates were then washed and a 1:2500 dilution of neutravidin conjugated to HRP (Molecular Probes) was added and incubated for 1 h at RT. Following a final wash, substrate and stopping solution were added as described above, and OD 450 determined. MAbs were biotinylated using EZLink Sulfo-NHS-LC-Biotin (Pierce) per manufacturer's instructions.
ELISAs to determine reactivity of MAbs with low pH treated virus were done in BSL-3 facilities with low passage lineage I WNV strain 3000.0259 NY 2000 (NY2000) (Ebel et al., 2001) . 360 ng/ml of NY2000 virus was added to each well of a 96-well plate and treated at pH 4 or pH 8 for 1 h at 37 8C by the addition of pH4 or pH 8 buffers. pH buffers consisted of DMEM no bicarbonate supplemented with 15 mM HEPES, 15 mM MES adjusted to either pH 4 or pH 8. After 1 h, the virus was back-neutralized to pH8, and ELISA coating buffer added. Virus was allowed to bind to the wells of the ELISA plate O/N at 4 8C. The plate was washed manually with PBS/0.05% Tween and blocked with BLOTTO for 1 h at 37 8C. MAbs were added at 0.1 mg/ml in BLOTTO, with the exception of 9E5 and 3F7 which were added at 0.2 mg/ml to increase the signal obtained from these MAbs, and incubated overnight at 4 8C. After washing, ECL anti-mouse IgG from sheep conjugated to HRP was added at a dilution of 1:10,000 and incubated for 1 h at RT. After a final wash, substrate and stopping solutions were added as described above and the OD 450 determined.
Affinity ELISAs to calculate the steady-state equilibrium constant value, Kd, of each MAb were performed by binding a 32-fold dilution of SVPs made in serum-free media to the wells of a 96-well plate. Plates were blocked and washed as described for the ELISA used for hybridoma screening described above. Dilutions of purified MAbs (from 88.7 nM to 0.005 nM) were incubated for 1 h at RT as the primary antibody. Secondary antibody and subsequent developing of the ELISA were done as for the ELISA used for hybridoma screening. The Kd was determined from the concentration of MAb corresponding to 50% maximal binding using GraphPad Prism 4.0 (GraphPad Software, Inc). Repeats of the ELISA with larger dilutions of SVPs did not affect the Kd values obtained (data not shown).
Immunoblotting and immunoprecipitation
Immunoblotting was performed using lysates of HEK 293T cells transfected with pCBWN or mock transfected, following the same transfection protocol used for production of SVPs. Cells were collected 48 h after transfection and lysed in 50 mM Tris pH7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton in PBS. SDS-PAGE was performed under completely denaturing (reducing agent added (DTT) and heat treatment at 55 8C for 10 min) or partially denaturing (non-reducing and kept at room temperature) conditions. Blots were blocked in BLOTTO, cut into strips and incubated with a 1:100 dilution of hybridoma supernatant (6G10), 1:500 dilution of ascites (10C5, 17D7, 11C2, 17C8, 8B10) or 1:500 dilution of WNV-specific hyperimmune ascitic fluid (W HIAF) (ATCC) in BLOTTO. Bound antibody was detected with ECL anti-mouse IgG from sheep conjugated to HRP (Amersham Biosciences) and enhanced chemiluminescence (SuperSignal West Femto Maximum Sensitivity Substrate, Pierce).
Immunoprecipitations were performed using lysates of HEK 293T cells transfected with pCBWN or mock transfected in a 6-well plate. Cells were metabolically labeled 24 h after transfection with 0.2 mCi per well of S 35 methioninecysteine overnight, and harvested 48 h after transfection (after overnight radiolabeling). Cell lysates were pre-cleared by incubation with 50 Al of Protein A/G beads (Protein A/G Plus-agarose, Santa Cruz Biotechnology) bound to 5 Ag of mouse IgG (Sigma) for 30 min at 4 8C with rotation. Lysates were subsequently incubated with 50 Al of Protein A/G beads bound to 5 Ag of each MAb for 2 h at 4 8C with rotation. Beads were then washed 4 times with PBS, pelleted and 30 Al of sample buffer with DTT added. After boiling, samples were analyzed by SDS-PAGE and radioactivity detected with a PhosphoImager.
Immunofluorescence
For immunofluorescence experiments to determine reactivity of MAbs, HeLa cells on coverslips were transfected with pCBWN following the protocol used for production of SVPs. Twenty-four hours after transfection, cells were fixed in 2% paraformaldehyde for 20 min at RT, washed with PBS and quenched with 50 mM ammonium chloride for 10 min. Cells were subsequently washed and permeabilized with 0.1% Triton for 5 min, washed with PBS and blocked with 5% FBS for 30 min. Cells were incubated with a 1:250 dilution of hybridoma supernatant from each MAb diluted in 5% FBS for 30 min. Cells were washed with PBS before a 30-min incubation with goat anti-mouse conjugated with AlexaFluor 594 (Molecular Probes) at 1:500 dilution in 5% FBS and a 1:500 dilution of DAPI (4V-6-Diamidino-2-phenylindole). Cells were washed, mounted with ProLong Antifade Kit (Molecular Probes) and examined on a Nikon E600 epifluorescence microscope.
For immunofluorescence experiments to determine crossreactivity of MAbs with other flaviviruses, Vero cells were infected with the specified virus and cells acetone fixed. All purified MAbs (3F7, 4E1, 9E5) were diluted to 10 Ag/ml in PBS. Ascites fluids (10C5, 11C2, 8B10, 6G10, 17D7, 17C8) were diluted 1:100 in PBS. Primary MAbs were incubated for 30 min at RT, washed with PBS then incubated with a second antibody-FITC conjugate consisting of affinity purified goat antibody to mouse IgG + IgM (Jackson ImmunoResearch) at 30 Ag/ml in counterstain blocking diluent (ViroStat) for 30 min at RT and rinsed with PBS. Mounting medium (ViroStat) was applied and slides coverslipped and examined under an Olympus BX40 Fluorescence Microscope at 400Â. Positive control MAbs included: Pan-Flavivirus (ViroStat), Pan-Alphavirus (ViroStat), Pan-Bunyavirus (ViroStat), Pan-Dengue (ViroStat), Yellow Fever Virus (ViroStat).
Protein production and purification
Monoclonal antibodies were purified from hybridoma supernatants using Protein A agarose (Invitrogen) with a Biologic LP chromatography system (BioRad). Prior to purification, Protein A MAPS II Binding Buffer (BioRad) was added to the supernatants according to manufacturer's instructions. Supernatants were subsequently filtered through a 0.22-Am-pore size filter. Protein A agarose columns were equilibrated with binding buffer, after which the hybridoma supernatant was applied. Columns were subsequently washed with binding buffer, and the MAbs eluted with elution buffer (Protein A MAPS II Elution Buffer, BioRad) in 10 ml fractions into tubes containing 1 ml of 1 M Tris pH 8.0 to back-neutralize the eluted MAb. Fractions containing eluted MAbs were concentrated and buffer exchanged with PBS using Apollo High Performance centrifugal spin concentrators (70 kDa MW cutoff, Continental Lab Products). Purity of MAbs was assessed by silver stain, and concentration measured by ELISA.
To measure IgG concentration by ELISA, plates were coated with a 1:500 dilution of coating antibody (Goat antimouse Ig (H + L)-Human adsorbed, Southern Biotechnology Associates) in ELISA coating buffer overnight at 4 8C. The plates were blocked in PBS/1%BSA/0.05% Tween 20, and dilutions of purified MAbs added and incubated for 1 h at RT. The same protocol for washing, secondary antibody and developing was used as described above for the ELISAs used for hybridoma screening. Dilutions of isotype-specific standard antibodies (Mouse Standard Panel, Southern Biotechnology Associates) were used to create a standard curve to determine the concentration of antibody in the purified batches of MAbs.
To express the small fragments of the E protein as bacterial fusion proteins, we used the pBAD/TOPO ThioFusion expression system (Invitrogen). Briefly, the fragments were amplified by PCR spanning the following residues of the E protein from WNV strain NY99-6480 (pCBWN): WE1 (AA 34-137), WE2 (AA146-249), WED3 (AA 296-415), WED3-1 (AA 296-338), WED3-2(AA 333-380), WED3-3 (AA 376-415), WE4 (AA130-193), WE5 (AA 188-248), WE6 (AA 242-301), WE7 (AA 1-52). The fragments were cloned into the pBAD/Thio TOPO expression vector by TA cloning. Insert containing plasmids were used to transform TOP10 Escherichia coli cells and 1-liter cultures grown and induced with arabinose, as specified by the manufacturer. Bacterial cell lysates were screened for protein expression by non-reducing SDS-PAGE, followed by detection with an anti-Histidine antibody which would detect the 6X-His tag on the C-terminus of each protein. Subsequently, binding of the MAbs to each fragment was assessed by SDS-PAGE under non-reducing conditions. A 1:500 dilution of ascites was used for MAbs 17D7, 17C8, 8B10, 6G10, 10C5 and 11C2, while a 1:100 dilution of hybridoma supernatant was used for MAbs 4E1, 3F7 and 9E5. For protein purification of fragments WE1, WE2 and WED3 for use in ELISA assays, 5-liter bacterial cultures were grown, induced with arabinose, and the proteins purified under denaturing conditions as specified by the manufacturer. Briefly, the bacterial pellets were lysed in denaturing lysis buffer (6 M guanidine hydrochloride, 100 mM NaH 2 PO 4 , 10 mM Tris-HCl), and the proteins purified by applying cleared lysates to nickel-NTA beads (Ni-NTA agarose, Qiagen) for 2 h with rotation. Beads were subsequently washed with 8 M urea, 100 mM NaH 2 PO 4 , 10 mM Tris-Cl, pH 8, and proteins eluted from beads with 8 M urea, 100 mM NaH 2 PO 4 , 10 mM Tris-Cl, pH 4.5. Purified proteins were dialyzed against PBS, quantified and purity assessed by silver stain. Purified fragments were used as antigen in ELISAs to detect binding of MAbs following a protocol as described above for the SVP ELISAs for hybridoma screening, except 500 ng of the purified fragment was used as the antigen and plated in each well instead of SVPs.
Plaque reduction neutralization assays
Plaque reduction neutralization assays were performed using WNV NY2000. BHK-21 Clone 15 cells were plated in a 12-well plate at 4 Â 10 5 cells/well, and allowed to attach for 3 h before infection. MAbs were diluted 4-fold (with concentrations starting at 250 Ag/ml) in 0.5 ml of DMEM with 10%FBS. 50-100 pfu of WNV was added to the dilutions of MAbs, and incubated for 1 h at 37 8C.
Media were then aspirated from the cells, and the virus/ MAb mixture added to the cells and allowed to infect for 1 h at 37 8C. After 1 h infection, the media were aspirated, and 1.5 ml of a 1:1 mixture of 2% SeaPlaque Low Melting Temperature agarose (Cambrex Bio Science Rockland, Inc) and 2Â Minimal Essential Medium (Gibco-BRL) with 8% FBS was added slowly to each well. Plates were incubated for 3 days at 37 8C in a CO 2 incubator. Cells were then fixed for 2-24 h with 10% formaldehyde, and after removal of agarose plugs, stained with 1% crystal violet in 20% ethanol. PRNT 50 values were obtained by averaging values from non-linear regression analysis of at least 4 replicates of the assay for each MAb, with R 2 values N 0.8 using GraphPad Prism 4.0 (GraphPad Software, Inc).
